Michelle Ols

492 total citations
11 papers, 373 citations indexed

About

Michelle Ols is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Michelle Ols has authored 11 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 5 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Michelle Ols's work include CAR-T cell therapy research (4 papers), Immunotherapy and Immune Responses (4 papers) and Immune Response and Inflammation (3 papers). Michelle Ols is often cited by papers focused on CAR-T cell therapy research (4 papers), Immunotherapy and Immune Responses (4 papers) and Immune Response and Inflammation (3 papers). Michelle Ols collaborates with scholars based in United States, China and Japan. Michelle Ols's co-authors include Mark J. Shlomchik, Daniel H. Kaplan, Boris Reizis, Michael Kashgarian, Lino L. Teichmann, Antony Rosen, Felipe Andrade, Herbert G. Bull, Jon T. Giles and Erika Darrah and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Immunity and Cancer Research.

In The Last Decade

Michelle Ols

11 papers receiving 366 citations

Peers

Michelle Ols
Michelle Ols
Citations per year, relative to Michelle Ols Michelle Ols (= 1×) peers Diana Celeste Salazar‐Camarena

Countries citing papers authored by Michelle Ols

Since Specialization
Citations

This map shows the geographic impact of Michelle Ols's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Ols with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Ols more than expected).

Fields of papers citing papers by Michelle Ols

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Ols. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Ols. The network helps show where Michelle Ols may publish in the future.

Co-authorship network of co-authors of Michelle Ols

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Ols. A scholar is included among the top collaborators of Michelle Ols based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Ols. Michelle Ols is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Inniss, Mara C., Sean G. Smith, Benjamin Primack, et al.. (2025). Carbonic anhydrase 2-derived drug-responsive domain regulates membrane-bound cytokine expression and function in engineered T cells. Communications Biology. 8(1). 28–28. 2 indexed citations
2.
Burga, Rachel A., Bülent Arman Aksoy, Zheng Ao, et al.. (2025). IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15. Molecular Therapy. 33(8). 3605–3623. 4 indexed citations
3.
Burga, Rachel A., Gauri Kulkarni, Zheng Ao, et al.. (2024). Abstract LB072: Tumor-infiltrating lymphocytes (TIL) engineered with membrane-bound IL15 (cytoTIL15 cells) exhibit pharmacologically regulatable signal transduction in cis and trans. Cancer Research. 84(7_Supplement). LB072–LB072. 1 indexed citations
4.
Koscsó, Balázs, Zheng Ao, Carmela Passaro, et al.. (2024). Abstract LB065: Tumor-infiltrating lymphocytes (TIL) engineered with regulatable membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) show enhanced efficacy in fibroblast-containing cold tumors. Cancer Research. 84(7_Supplement). LB065–LB065. 2 indexed citations
5.
Pedro, Kyle D., Rachel A. Burga, Gauri Kulkarni, et al.. (2023). Abstract LB096: IL15-engineered tumor infiltrating lymphocytes (cytoTIL15TM) exhibit activity against autologous tumor cells from multiple solid tumor indications without IL2. Cancer Research. 83(8_Supplement). LB096–LB096. 4 indexed citations
6.
Tchaicha, Jeremy H., Rachel A. Burga, Benjamin Primack, et al.. (2022). Abstract LB212: Allogeneic, IL-2-independent tumor-infiltrating lymphocytes expressing membrane-bound IL-15 (cytoTIL15) eradicate tumors in a melanoma PDX model through recognition of shared tumor antigens. Cancer Research. 82(12_Supplement). LB212–LB212. 1 indexed citations
7.
Burga, Rachel A., Kyle D. Pedro, Jacques P. Tremblay, et al.. (2021). 1008P cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility. Annals of Oncology. 32. S852–S852. 1 indexed citations
8.
Ols, Michelle, Jaime L. Cullen, Adriana Turqueti‐Neves, Josephine R. Giles, & Mark J. Shlomchik. (2016). Dendritic Cells Regulate Extrafollicular Autoreactive B Cells via T Cells Expressing Fas and Fas Ligand. Immunity. 45(5). 1052–1065. 25 indexed citations
9.
Darrah, Erika, Jon T. Giles, Michelle Ols, et al.. (2013). Erosive Rheumatoid Arthritis Is Associated with Antibodies That Activate PAD4 by Increasing Calcium Sensitivity. Science Translational Medicine. 5(186). 186ra65–186ra65. 135 indexed citations
10.
Sweet, Rebecca A., et al.. (2011). Facultative role for T cells in extrafollicular Toll-like receptor-dependent autoreactive B-cell responses in vivo. Proceedings of the National Academy of Sciences. 108(19). 7932–7937. 55 indexed citations
11.
Teichmann, Lino L., Michelle Ols, Michael Kashgarian, et al.. (2010). Dendritic Cells in Lupus Are Not Required for Activation of T and B Cells but Promote Their Expansion, Resulting in Tissue Damage. Immunity. 33(6). 967–978. 143 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026